Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Completed
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.
Gender:
ALL
Ages:
All
Trial Updated:
07/07/2012
Locations: Texas Oncology, P.A., Arlington, Texas +14 locations
Conditions: Non-small Cell Lung Cancer
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma
Completed
Primary Objectives: 1. To determine the toxicity profile of multiple doses of bortezomib when given with ICE in patients with relapsed and refractory classical Hodgkin lymphoma (HL). 2. To determine the maximum tolerated dose (MTD) of bortezomib when given in combination with ICE chemotherapy in patients with relapsed and refractory classical Hodgkin lymphoma (HL). Secondary Objectives: - To determine the overall response rate and complete response rate in patients with relapsed and refractor... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/05/2012
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Hodgkin Lymphoma, Lymphoma
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Completed
To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2012
Locations: Pfizer Investigational Site, Houston, Texas
Conditions: Neoplasms
Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy
Terminated
Primary Objectives: 1. To test whether the addition of chemotherapy to radiotherapy improves the progression-free survival for patients with stage I, II and IIIa malignant mixed mesodermal tumor (MMMT) of the uterus. 2. To determine the acute and late toxicity profiles associated with this treatment regimen. 3. To describe the effect of this treatment regimen on the patient's quality of life.
Gender:
FEMALE
Ages:
All
Trial Updated:
09/13/2011
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Uterine Neoplasms
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
Completed
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2011
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas +3 locations
Conditions: Non-Small Cell Lung Cancer
A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors
Completed
This clinical research study is being conducted to investigate the effectiveness of combining carboplatin and irinotecan, versus irinotecan alone, in treating children who have refractory solid tumors.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
04/07/2011
Locations: Local Institution, Houston, Texas
Conditions: Neoplasms
Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
Unknown
This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with carboplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2011
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Glioblastoma Multiforme
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Unknown
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2011
Locations: Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas +1 locations
Conditions: Lung Cancer
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining chemotherapy with peripheral stem cell transplantation in treating children who have central nervous system cancer.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
02/25/2011
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell or bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy. PURPOSE: This phase I trial is studying the side effects and best dose of combination chemotherapy whe... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
10/14/2010
Locations: Texas Children's Cancer Center, Houston, Texas
Conditions: Neuroblastoma
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
Terminated
The purpose of this study is to help answer: * Whether pemetrexed, gemcitabine and/or carboplatin can shrink tumor(s) or make tumor(s) disappear in patients with relapsed lung cancer (lung cancer that has come back after surgical removal and chemotherapy), and to determine how long this will last * Whether pemetrexed, gemcitabine and/or carboplatin can help patients with relapsed lung cancer live longer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2010
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas
Conditions: Lung Neoplasms
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Completed
The purpose of the study is to determine if the combination of cetuximab, carboplatin and paclitaxel will shrink a specific type of lung cancer known as non-small cell lung cancer (NSCLC). The safety of this combination will also be evaluated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2010
Locations: ImClone Investigational Site, Houston, Texas +1 locations
Conditions: Non-small Cell Lung Cancer